SCHEMBL24317271

SCHEMBL24317271

O=C1c2cccc3cccc(c23)N1c1ccc(=O)[nH]c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
MEN1 O00255 3/20 0.52
PDE6D O43924 1/20 0.49
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CASP1 P29466 2/20 0.43
MPI P34949 1/20 0.43
CACNA1B Q00975 1/20 0.43
APBA1 Q02410 1/20 0.43
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
UBE2N P61088 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 3/20 0.40
POLB P06746 1/20 0.40
GAA P10253 3/20 0.39
ERCC1 P07992 1/20 0.39
FEN1 P39748 1/20 0.39
ERCC4 Q92889 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317276 0.84 PDE6D (0.50) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL24317274 0.80 KMT2A (0.52) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL24317273 0.80 KMT2A (0.52) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL24317277 0.80 PDE6D (0.46) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL24317270 0.74 PDE6D (0.49) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL24317272 0.74 PDE6D (0.46) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL10869116 0.73 PDE6D (0.81) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL9290285 0.73 PDE6D (0.61) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL24317515 0.71 KMT2A (0.52) KMT2AMEN1PDE6DALDH1A1HPGD
SCHEMBL9290287 0.70 PDE6D (0.82) KMT2AMEN1PDE6DALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 KMT2A 1903/4885MEN1 728/4885PDE6D 4836/4885
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 KMT2A 1574/4885MEN1 2331/4885PDE6D 4671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.